Quarterly ResultAug 12, 2026, 05:23 PM
RADNOSTIX Q2 Net Loss Widens to $(882K); Sales Down 27%
AI Summary
RADNOSTIX INC. reported a significant widening of its net loss for the second quarter of 2026 to $(881,997) from $(160,785) in the prior year, with sales of product decreasing by 26.9% to $2.67 million. Year-to-date, the net loss expanded to $(2.23) million, and the company experienced negative cash flow from operations. Key strategic developments include the mutual termination of a $12.5 million asset sale for its Fluorine Products segment, the acquisition of assets from Lucerno Dynamics, LLC, and the extension and modification of several promissory notes.
Key Highlights
- Q2 2026 net loss widened to $(881,997) from $(160,785) in Q2 2025.
- Q2 2026 sales of product decreased 26.9% to $2.67 million from $3.66 million in Q2 2025.
- YTD June 30, 2026 net loss increased to $(2.23) million from $(273,479) in 2025.
- Net cash used in operating activities was $(686,000) YTD 2026, compared to $310,446 provided YTD 2025.
- Mutually terminated a $12.5 million asset sale agreement for the Fluorine Products segment.
- Acquired assets from Lucerno Dynamics, LLC for the Medical Devices segment.
- Extended maturity dates of 2013, 2018, and 2019 Promissory Notes to March 31, 2031.
- Issued a new $500,000 Promissory Note from Kershner Grosso & Co.
Price Impact
More from INIS